论文部分内容阅读
目的:探讨中药灌肠加芒硝敷脐治疗原发性肝癌腹水的临床疗效。方法:共收集原发性肝癌腹水患者72例,将患者分治疗组与对照组各36例,治疗组(常规综合治疗+中药灌肠+芒硝敷脐),对照组(常规综合治疗),疗程10天,疗程结束后评价两组患者治疗后腹水改善情况;腹围、体重、平均24小时尿量的变化情况;临床常见症状总积分改善程度;生活质量改善情况。观察不良反应,随访一个月。结果:1治疗后两组腹水疗效比较:治疗组总有效率65.71%,对照组总有效率42.86%,两组间差异有统计学意义(P<0.01)。2在体重、平均24小时尿量、腹围变化方面,治疗组疗效均优于对照组(P<0.05)。3在临床常见症状总积分、患者生活质量改善方面治疗组疗效优于对照组,治疗后组间比较均有统计学意义(P<0.05,P<0.01)。结论:中药灌肠配合芒硝敷脐治疗原发性肝癌腹水是安全有效的,值得在临床推广。
Objective: To investigate the clinical efficacy of traditional Chinese medicine enema plus Glauber’s Umbilicus in the treatment of ascites of primary liver cancer. Methods: A total of 72 patients with primary liver cancer with ascites were collected. The patients were divided into treatment group and control group with 36 cases each. The treatment group (conventional combined therapy + Chinese medicine enema + Glauber’s umbilicus), control group (conventional combined therapy), treatment 10 Day after treatment, the improvement of ascites in both groups after treatment was evaluated; the change of abdominal circumference, body weight and average 24-hour urine output; the improvement of the total score of clinical common symptoms; and the improvement of quality of life. Adverse reactions were observed and followed up for one month. Results: 1 Comparison of the therapeutic effect of ascites between the two groups: The total effective rate was 65.71% in the treatment group and 42.86% in the control group, with significant difference between the two groups (P <0.01). The body weight, average 24-hour urine output, abdominal circumference changes, the treatment group were better than the control group (P <0.05). The curative effect of the treatment group was better than that of the control group in the clinical total score of common symptoms and the quality of life of the patients. There was significant difference between the two groups after treatment (P <0.05, P <0.01). Conclusion: It is safe and effective to treat ascites of primary hepatocellular carcinoma with Chinese medicine enema and Glauber’s umbilical application, which is worthy of clinical promotion.